Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Teva Pharmaceutical Industries Limited before investing.

In this article, we go over a few key elements for understanding Teva Pharmaceutical Industries Limited’s stock price such as:

• Teva Pharmaceutical Industries Limited’s current stock price and volume
• Why Teva Pharmaceutical Industries Limited’s stock price changed recently
• Upgrades and downgrades for TEVA from analysts
• TEVA’s stock price momentum as measured by its relative strength

About Teva Pharmaceutical Industries Limited (TEVA)

Before we jump into Teva Pharmaceutical Industries Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Want to learn more about Teva Pharmaceutical Industries Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited’s Stock Price as of Market Close

As of December 02, 2025, 10:05 AM, CST, Teva Pharmaceutical Industries Limited’s stock price was $26.910.

Teva Pharmaceutical Industries Limited is up 0.71% from its previous closing price of $26.720.

During the last market session, Teva Pharmaceutical Industries Limited’s stock traded between $26.680 and $27.040. Currently, there are approximately 1,147.00 million shares outstanding for Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited’s price-earnings (P/E) ratio is currently at 43.6, which is high compared to the Pharmaceuticals industry median of 21.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Teva Pharmaceutical Industries Limited Stock Price History

Teva Pharmaceutical Industries Limited’s (TEVA) price is currently up 0.07% so far this month.

During the month of December, Teva Pharmaceutical Industries Limited’s stock price has reached a high of $27.040 and a low of $26.460.

Over the last year, Teva Pharmaceutical Industries Limited has hit prices as high as $26.960 and as low as $12.465. Year to date, Teva Pharmaceutical Industries Limited’s stock is up 22.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Teva Pharmaceutical Industries Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there was 1 analyst who downgraded Teva Pharmaceutical Industries Limited’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Teva Pharmaceutical Industries Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Teva Pharmaceutical Industries Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Teva Pharmaceutical Industries Limited’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Teva Pharmaceutical Industries Limited (TEVA) by visiting AAII Stock Evaluator.

Relative Price Strength of Teva Pharmaceutical Industries Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Teva Pharmaceutical Industries Limited has a weighted four-quarter relative price strength of 14.95%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Teva Pharmaceutical Industries Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Teva Pharmaceutical Industries Limited Stock Price: Bottom Line

As of December 2, 2025, Teva Pharmaceutical Industries Limited’s stock price is $26.910, which is up 0.71% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Teva Pharmaceutical Industries Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.